XOMA (XOMA, Financial) stock experienced a significant rise of 5.17%, reaching $27.35 per share. The trading volume was 5,091 shares, resulting in a turnover rate of 0.04% and a price fluctuation of 1.92%.
Recent financial reports show XOMA achieved revenue of $11.09 million, net profit of $15.99 million, and earnings per share (EPS) of $0.88. The company's gross profit was $11.08 million, with a price-to-earnings (P/E) ratio of -12.39.
Among the three institutions providing ratings, 67% recommend buying the stock, while 33% suggest holding it.
In the broader biotechnology industry, where XOMA operates, the overall decline was 0.43%. Notable performers included Coeptis Therapeutics Holdings Inc., Nkgen Biotech Inc., and Capricor Therapeutics, Inc. Active stocks in the same sector were Aditxt, Inc., Gri Bio, Inc., and Seelos Therapeutics, Inc., with turnover rates of 165.20%, 56.01%, and 55.34%, respectively. Stocks with significant price fluctuations included Coeptis Therapeutics Holdings Inc., Tc Biopharm (Holdings) Plc, and Capricor Therapeutics, Inc., with amplitudes of 87.30%, 85.25%, and 45.53%.
XOMA Royalty Corp is a biotechnology royalty aggregation company that plays a crucial role in helping biotech firms achieve their health improvement goals. XOMA benefits economically from the success of licensed pre-commercial therapies. This structure provides non-dilutive, non-recourse funding to the sellers, which can be used to advance their drug candidates or for general corporate purposes.
